Fig. 2

Antibodies from baseline sera of melanoma patients are associated with ICI toxicity. a Volcano plot of differential antibody levels from baseline sera comparing none/mild vs. severe toxicity for anti-CTLA-4-treated patients (n = 37). Filtered antibodies are highlighted in blue, and curated antibodies are indicated in red (downregulated with severe toxicity) or purple (upregulated with severe toxicity). b As for a, but comparing no/mild vs. severe toxicity for anti-PD-1-treated patients (n = 27). c As for a, but comparing mild vs. severe toxicity for anti-CTLA-4 and anti-PD-1 combination treated patients (n = 11). d Boxplots showing probe intensities for the 15 most differentially expressed antibodies (DE; based on p values) between sera from antiCTLA-4 patients (n = 37) with no/mild toxicity (blue) vs. those with severe toxicity (orange). Data represent median probe intensities ± sd. e As for d, but for samples comparing no/mild vs. severe toxicity for anti-PD-1-treated patients (n = 27). f As for d, but for samples comparing mild vs. severe toxicity for combination anti-CTLA-4 and anti-PD-1-treated patients (n = 11)